Dexamethasone

DRUG INFORMATION

  ADULT
    - For Oral Administration The initial dosage varies from 0.75 mg to 9 mg a day
      depending on the disease being treated.
      Source: US FDA label for dexamethasone (Dexamethasone), section 'dosage and
      administration', retrieved 2026-08-29
    - In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30
      mg of dexamethasone for a week followed by 4 mg to 12 mg every other day for one
      month have been shown to be effective (see PRECAUTIONS : Neuro-Psychiatric ).
      Source: US FDA label for dexamethasone (Dexamethasone), section 'dosage and
      administration', retrieved 2026-08-29
    - The range of initial doses is 0.02 mg to 0.3 mg/kg/day in three or four divided
      doses (0.6 mg to 9 mg/m 2 bsa/day).
      Source: US FDA label for dexamethasone (Dexamethasone), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The efficacy and safety of corticosteroids in the pediatric population are based
      on the well-established course of effect of corticosteroids, which is similar in
      pediatric and adult populations. Published studies provide evidence of efficacy
      and safety in pediatric patients for the treatment of nephrotic syndrome (patients
      >2 years of age), and aggressive lymphomas and leukemias (patients >1 month of
      age).
      Source: US FDA label for dexamethasone (Dexamethasone), section 'pediatric use',
      retrieved 2026-08-29
    - For Oral Administration The initial dosage varies from 0.75 mg to 9 mg a day
      depending on the disease being treated. It Should Be Emphasized That Dosage
      Requirements Are Variable And Must Be Individualized On The Basis Of The Disease
      Under Treatment And The Response Of The Patient.
      Source: US FDA label for dexamethasone (Dexamethasone), section 'dosage and
      administration', retrieved 2026-08-29
    - The range of initial doses is 0.02 mg to 0.3 mg/kg/day in three or four divided
      doses (0.6 mg to 9 mg/m 2 bsa/day).
      Source: US FDA label for dexamethasone (Dexamethasone), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for dexamethasone (Dexamethasone),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for dexamethasone (Dexamethasone),
      retrieved 2026-08-29

  PREGNANCY
    - Teratogenic Effects: Corticosteroids have been shown to be teratogenic in many
      species when given in doses equivalent to the human dose.
      Source: US FDA label for dexamethasone (Dexamethasone), section 'pregnancy',
      retrieved 2026-08-29
    - Animal studies in which corticosteroids have been given to pregnant mice, rats,
      and rabbits have yielded an increased incidence of cleft palate in the offspring.
      Source: US FDA label for dexamethasone (Dexamethasone), section 'pregnancy',
      retrieved 2026-08-29
    - There are no adequate and well-controlled studies in pregnant women.
      Source: US FDA label for dexamethasone (Dexamethasone), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Systemically administered corticosteroids appear in human milk and could suppress
      growth, interfere with endogenous corticosteroid production, or cause other
      untoward effects.
      Source: US FDA label for dexamethasone (Dexamethasone), section 'nursing mothers',
      retrieved 2026-08-29
    - Because of the potential for serious adverse reactions in nursing infants from
      corticosteroids, a decision should be made whether to discontinue nursing or to
      discontinue the drug, taking into account the importance of the drug to the
      mother.
      Source: US FDA label for dexamethasone (Dexamethasone), section 'nursing mothers',
      retrieved 2026-08-29